Podcast Episodes
Back to Search301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in …
2 years, 6 months ago
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the …
2 years, 6 months ago
299: Live! From the STAT Breakthrough Summit East
Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Fen…
2 years, 7 months ago
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug devel…
2 years, 7 months ago
297: VC turmoil, GLP-1 competition, & the war on recovery
For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us …
2 years, 7 months ago
296: Legal insider trading, booming biotech stocks, & the next GLP-1
We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone t…
2 years, 7 months ago
295: Humira’s legacy, CEO symbolism, and genomic surgery
First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard G…
2 years, 8 months ago
294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking
The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STA…
2 years, 8 months ago
293: AI in medicine, detangling hype, and Icelandic DNA
It's our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technol…
2 years, 8 months ago
292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon
We explain the debate over Vertex Pharmaceuticals' novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about …
2 years, 8 months ago